Human insulin is a synthetic insulin grown in the laboratory, which imitates the functioning of insulin already present in the human body.
The use of human insulin is fairly recent and animal insulin (most often porcine insulin) was used by medical practitioners before that.

Browse the full Global Human Insulin Market Report: http://www.mrrse.com/human-insulin-market

The growth of the human insulin market is primarily attributed to the alarming rise in obese and diabetic population across the globe. According to the WHO, an estimated 1.5 million people died in 2012 as a direct result of diabetes.
This disease is likely to become the 7th leading cause of death by 2030. The WHO further reveals that in 2014 alone, 1.9 billion adults were considered to be overweight, 600 million of which were obese.
Healthy Growth in Store for Global Human Insulin Market
According to a report by Persistence Market Research, the global market for human insulin is projected to grow from a value of US$24,332.6 million in 2014 to that of US$49,197.3 million by 2020 at a strong growth rate of 12.4% during that period.
Here’s a look at some of the factors that have an impact on the global human insulin market.
Growth Boosters
• Rise in geriatric population
• Increasing prevalence of lifestyle-related disorders such as obesity and diabetes
• Strong pipeline and development of molecules from a newer class of drugs for diabetes
• Availability of technologically advanced human insulin infusion devices in developed markets such as North America
• Rising research and development investments in Japan
• Availability of large number of drug manufacturing companies in developing countries
• Increase in disposable income and patient pool in emerging economies such as China and India
• Growth of medical tourism in the Middle East (Saudi Arabia, Qatar, Egypt, and the UAE) and Latin America (Brazil and Mexico)
• Growing awareness about diabetes and related disorders
Growth Challenges
• Uneven pricing in developing countries
• Limited access to advanced human insulin infusion devices in emerging countries
• Strict regulatory requirements for drug approval
Competitive Nature of the Vendor Landscape

Request Send An Enquiry: http://www.mrrse.com/enquiry/165

Chapter 1 Preface
1.1 Report Description
1.2 Research Methodology
1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter’s Five Forces Analysis
3.1 Bargaining Power of Suppliers
3.2 Bargaining Power of Buyers
3.3 Threat of New Entrants
3.4 Threat of Substitutes
3.5 Intensity of Rivalry

Chapter 4 Industry Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Growing prevalence of diabetes
4.2.2 Technological advancements in human insulin delivery devices
4.2.3 Increasing awareness among people towards diabetes care
4.3 Impact Analysis of Market Drivers
4.4 Market Restraints
4.4.1 Uneven pricing and limited access to human insulin in emerging countries
4.4.2 Strict regulatory requirements for drug approval
4.5 Impact Analysis of Market Restraints
4.6 Market Trends
4.6.1 Increasing usage of insulin pens for administration of human insulin

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Type
6.1 Traditional Human Insulin
6.2 Modern Human Insulin

Chapter 7 Market Size and Forecast of Traditional Human Insulin by Type
7.1 Short-acting Human Insulin
7.2 Intermediate-acting Human Insulin
7.3 Premixed Human Insulin

Chapter 8 Market Size and Forecast of Modern Human Insulin by Type
8.1 Rapid-acting Human Insulin
8.2 Long-acting Human Insulin
8.3 Premixed Human Insulin

Chapter 9 Market Size and Forecast by Disease
9.1 Type 1 Diabetes
9.2 Type 2 Diabetes

Chapter 10 Market Size and Forecast by Brand
10.1 Traditional Human Insulin Brand
10.2 Modern Human Insulin Brand
The worldwide human insulin market is rather competitive, given the strong presence of leading drug manufacturers across the globe. Some of the prominent names in the human insulin market are Bristol-Myers Squibb Company, Eli Lilly and Company, Wockhardt, Tonghua Dongbao Pharmaceutical Co., Ltd., Oramed Pharmaceuticals, Inc., Biocon, GlaxoSmithKline Plc, Novo Nordisk A/S, Pfizer, Inc., Merck & Co., Inc., Julphar, ADOCIA, and Sanofi.

Browse the full Press Release of Global Human Insulin Market: http://www.mrrse.com/global-human-insulin-market

The demand for modern human insulin surpasses that of traditional insulin. According to Persistence Market Research, the value of the modern human insulin segment is projected to rise from US$19,526.8 million in 2014 to US$40,987.1 million by 2020. Some of the leading brands of modern human insulin available today are Levemir, Apidra, Novomix, Humalog, Novolog, and Lantus. Given the effective results provided by modern human insulin over the traditional kind, the market for the former is forecast to grow at a 13.2% CAGR by 2020.
The introduction of innovative and advanced insulin infusion devices and aids such as the insulin pen will be the driving force of the human insulin market in the coming years.

About Us:
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.
MRRSE’s interface is tailored to provide all possible information about a market research report via a simple, snappy layout. Our refined algorithm returns specific results from hundreds of thousands of reports that lie in our database. Users can search for market research reports according to industries, sub-industries, company names or countries.
Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: [email protected]
Website: http://www.mrrse.com/